Mizuho raised the firm’s price target on Guardant Health (GH) to $70 from $65 and keeps an Outperform rating on the shares following the investor day. The firm thinks the stock had a negative reaction due to the guide-down in implied volumes. However, it views the U.S. Preventive Services Task Force guideline delay as an expected headwind, and now sees the Shield ramp as “believable.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health’s Strong Growth Trajectory and Unique Oncology Approach Earns Buy Rating
- Wolfe upgrades Guardant to Outperform after ‘solid’ analyst day
- Guardant Health price target raised to $70 from $60 at JPMorgan
- Guardant Health upgraded to Outperform from Peer Perform at Wolfe Research
- Guardant Health price target raised to $80 from $70 at UBS